Oncology Podcasts

Episode 1

Xofigo

Why treat with Xofigo
®▼
(radium-223 dichloride)?

Description

Listen to experts in the field as they discuss the benefits and challenges of treatment with radium-223 dichloride and why they consider it as an option for eligible metastatic castration-resistant prostate cancer (mCRPC) patients in their clinics.

Speakers:

  • Dr Omi Parikh - Consultant Clinical Oncologist
  • Ellie Cradock Molecular Radiotherapy Manager

 

This promotional podcast series has been initiated and funded by Bayer and is for healthcare professionals only.

Speakers
    • Dr.-Omi-ParikhDr Omi Parikh

    Consultant Clinical Oncologist at the Lancashire Teaching Hospitals NHS Foundation Trust and is Chair of the Lancashire & South Cumbria Urology Network Site Specific Group.

    Dr Parikh completed her undergraduate medical training at the University of Edinburgh and her general medical training in Edinburgh and London. Following this, she undertook her specialist registrar training in London and registered in 1999. Her interests are urological cancers. In the past 15 years, she has co-authored over 30 peer reviewed articles and has expertise in prostate cancer, renal cell carcinoma, and bladder cancer. Dr Parikh is an investigator in multiple prostate, bladder and renal cancer trials and is involved in phase 1, 2 and 3 trials.

    • Ellie-CradockEllie Cradock

    Lead Molecular Radiotherapy Manager at the University Hospitals Bristol NHS Foundation Trust.

    Ellie trained as a Therapeutic Radiographer and has over 10 years’ experience working on linear accelerators, understanding the patient experience of a cancer diagnosis and how to provide holistic support through a treatment journey. Ellie has worked in Molecular Radiotherapy since 2015 and has had the privilege of setting up both Molecular Radiotherapy trials as well as new services in close collaboration with the many supporting departments that help make a complex service, such as this, work.

Episode 2
Optimising patient identification and referral — Xofigo®▼ (radium-223 dichloride)
PP-XOF-GB-0463, February 2024
Episode 3
The Practicalities of Treatment — Xofigo®▼ (radium-223 dichloride)
PP-XOF-GB-0464, February 2024

PP-XOF-GB-0462 | February 2024